Trevi Therapeutics director granted 35,000 stock options
Trevi Therapeutics director Michael Thomas Heffernan received a grant of stock options covering 35,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Trevi Therapeutics director Michael Thomas Heffernan received a grant of stock options covering 35,000 shares of common stock. The nonstatutory stock option has an exercise price of $13.45 per share and expires on June 2, 2036. The award was granted for his service as a director and will fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting, as long as he continues serving the company. Following this grant, he holds 35,000 options directly under this award.
Insider Trade Summary
Grant/Award: 35,000 shares
Grant/Award
1 txn
Insider
Heffernan Michael Thomas
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Nonstatutory Stock Option (right to buy) | 35,000 | $0.00 | $0.00 |
Holdings After Transaction:
Nonstatutory Stock Option (right to buy) — 35,000 contracts (Direct)
Footnotes (1)
- F1. This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Key Figures
Option grant size: 35,000 options
Exercise price: $13.45 per share
Underlying shares: 35,000 shares
+3 more
6 metrics
Option grant size
35,000 options
Nonstatutory stock option award to director
Exercise price
$13.45 per share
Price to buy underlying Trevi Therapeutics common stock
Underlying shares
35,000 shares
Common stock covered by the option grant
Grant date
June 3, 2026
Date the option was granted
Expiration date
June 2, 2036
Option term end for this grant
Shares after transaction
35,000 options
Total derivative holdings from this award following grant
Key Terms
Nonstatutory Stock Option, exercise price, underlying security, expiration date, +1 more
5 terms
Nonstatutory Stock Option financial
"Nonstatutory Stock Option (right to buy)"
A nonstatutory stock option (also called a non-qualified stock option) is an employee or contractor right to buy company shares at a set price that does not qualify for special tax treatment. When exercised, the difference between the market price and the set price is treated as ordinary income for the recipient and usually triggers payroll tax and withholding. For investors, these options matter because they create potential share dilution, affect reported compensation costs, and influence the timing of when new shares enter the market—similar to a coupon that lets someone buy stock at a discount but results in an immediate tax bill.
exercise price financial
"conversion_or_exercise_price: "13.4500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title: "Common Stock""
expiration date financial
"expiration_date: "2036-06-02T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"This option is scheduled to fully vest on the earlier of (i) the first anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Michael Thomas Heffernan report in his Trevi Therapeutics (TRVI) Form 4?
Heffernan reported receiving a grant of 35,000 nonstatutory stock options in Trevi Therapeutics. These options give him the right to buy common shares at a fixed price, reflecting equity-based compensation for his role as a director.
How many Trevi Therapeutics (TRVI) options were granted to the director?
The Form 4 shows a grant of 35,000 stock options to director Michael Thomas Heffernan. Each option relates to one share of common stock, so the award covers 35,000 underlying common shares in total under this single grant.
What is the exercise price of Michael Heffernan’s Trevi Therapeutics (TRVI) options?
The options have an exercise price of $13.45 per share. This means Heffernan can buy Trevi Therapeutics common stock at $13.45 for each of the 35,000 shares covered, regardless of future market price movements during the option term.
When do Michael Heffernan’s Trevi Therapeutics (TRVI) options vest?
The options are scheduled to fully vest on the earlier of the first anniversary of the June 3, 2026 grant date or the next annual stockholder meeting. Vesting depends on his continued service as a director, employee, or consultant of Trevi Therapeutics.
What is the expiration date of the Trevi Therapeutics (TRVI) options granted to Heffernan?
The options expire on June 2, 2036. After that date, Heffernan can no longer use them to purchase Trevi Therapeutics common shares, so any unexercised portion would lapse automatically at expiration.
Is the Trevi Therapeutics (TRVI) option grant to Michael Heffernan an open‑market purchase?
No, it is a compensation grant classified as a nonstatutory stock option. The Form 4 transaction code shows it as a grant or award, meaning the options were issued by the company rather than bought in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates